Absence of myocardial protection with prostacyclin during cardiac arrest

Prostaglandins Leukot Med. 1986 Sep;24(1):87-92. doi: 10.1016/0262-1746(86)90211-8.

Abstract

Prostacyclin (PGI2) has been shown to present myocardial protective effects which could be beneficial during cardiac arrest. We tested this hypothesis in a closed-chest dog model in which electromechanical dissociation (EMD) can be predictably observed after 90 to 120 seconds of ventricular fibrillation without chest compression. Six dogs were pretreated with a PGI2 infusion at a rate of 1 mcg/kg/min and six other dogs served as control animals. After 60 seconds of ventricular fibrillation, EMD was already observed in 3 PGI2-treated dogs but in no control dog. After 90 seconds of ventricular fibrillation, EMD was present in 2 PGI2-treated dogs and in 2 control dogs, so that 4 control but only one PGI2-treated animal survived after 90 seconds of ventricular fibrillation. Ventricular defibrillation was also not facilitated in PGI2-treated dogs. The present study does not support PGI2 administration in cardiopulmonary resuscitation.

MeSH terms

  • Animals
  • Dogs
  • Epoprostenol / pharmacology
  • Epoprostenol / therapeutic use*
  • Heart Arrest / drug therapy*
  • Hemodynamics / drug effects
  • Resuscitation / methods
  • Ventricular Fibrillation / drug therapy

Substances

  • Epoprostenol